Published on 18/12/2025
WHO Prequalification Program for Medicines: Eligibility, Process & Benefits
Step 1: Understanding WHO Prequalification Program
The WHO Prequalification (PQ) Program is designed to promote access to safe, effective, and quality medicines in low and middle-income countries by ensuring these products meet internationally accepted quality standards. This is accomplished through a rigorous assessment process based on the principles of Good Manufacturing Practices (GMP). For any organization aiming to submit medicines for WHO prequalification, understanding this program’s framework is crucial.
The primary focus of the WHO PQ program is to provide an independent assessment of medicines across various therapeutic areas. It allows manufacturers to demonstrate that their products meet WHO quality requirements, thus enhancing their market attractiveness especially for procurement agencies. Achieving PQ status can therefore be critical for manufacturers seeking to tap into the global health market.
Regulatory compliance consulting professionals play a key role in navigating the complex PQ process. Their knowledge is
Moreover, the PQ program is crucial for prequalified products as it bolsters trust and acceptance among governments and NGOs when making procurement decisions. This trust is built by providing solid documentation of manufacturing processes and quality controls that align with WHO GMP standards, as detailed in WHO TRS (Technical Report Series).
In the following sections, we will explore eligibility requirements, the application process, and benefits of obtaining PQ status. This comprehensive understanding will prepare organizations for successful engagement with the program, enhancing their positioning in both local and global markets.
Step 2: Assessing Eligibility for WHO Prequalification
Before initiating the prequalification submission process, manufacturers must confirm they meet the eligibility criteria set forth by WHO. This includes product and manufacturer characteristics that align with the prequalification framework. The eligibility assessment is essential in avoiding unnecessary expenditure on applications that are unlikely to be considered due to non-compliance with WHO standards.
The basic eligibility criteria for the WHO PQ program include:
- The product must be a pharmaceutical preparation intended for human use.
- The medication should be listed on the WHO Essential Medicines List or should fulfill a specific public health need.
- The manufacturing facility must demonstrate that it conforms to WHO GMP, which entails strict compliance with quality assurance and environment control measures.
Moreover, manufacturers should evaluate whether they possess the necessary quality control systems in place to provide stability data and ensure consistent production quality over time. For example, ongoing stability studies should be performed under various conditions to maintain product integrity across its shelf life. Also, manufacturers should have a robust system for batch release, which must adhere to stringent testing and evaluation processes before commercialization.
For companies contemplating entry into the WHO PQ program, a comprehensive gap analysis against the eligibility criteria is recommended. Engaging in regulatory compliance consulting can aid companies in identifying potential gaps in their current processes or documentation. This analysis will highlight areas requiring improvement and outline the steps necessary to comply with WHO regulations.
Step 3: Preparing Documentation for WHO Prequalification
The preparation of documentation is a critical step in the WHO prequalification process. The submission Dossier must adhere to the Common Technical Document (CTD) format endorsed by ICH (International Council for Harmonisation). This format streamlines the regulatory submissions for health authorities globally and facilitates consistent assessment practices.
Essential components of the dossier include:
- Quality (Module 2 and 3): Detailed information about the drug substance, drug product, and manufacturing processes. This section demonstrates compliance with WHO GMP requirements.
- Nonclinical Study Reports (Module 4): Data from preclinical studies that ascertain the safety profile of the drug.
- Clinical Study Reports (Module 5): Data from clinical trials outlining efficacy and safety data, including statistical analyses.
Within the Quality section, manufacturers must provide comprehensive descriptions of the manufacturing process, including flowcharts, raw material specifications, site information for all locations involved in production, and storage conditions. Inspection readiness documentation should also be prepared, as WHO may conduct on-site inspections to verify adherence to the GMP standards outlined in WHO TRS.
Additionally, it’s crucial to ensure that the stability studies are properly documented and follow internationally accepted testing parameters. This includes having stability data that complies with ICH guidelines for various temperatures and environmental conditions the product may encounter during shipping and storage.
Regulatory compliance consulting may assist in identifying gaps in the documentation, ensuring that all necessary details are adequately covered. This can include compiling necessary certificates, quality metrics, and test data, which would collectively establish a compelling submission package.
Step 4: Submitting the Dossier to WHO
The submission of the dossier to WHO is a crucial step that demands thorough attention to detail. It’s important to comply with the submission guidelines as outlined on the official WHO Prequalification webpage. The initial submission can be done via a secure online portal or by sending hard copies of the dossier to the WHO point of contact.
Before submission, manufacturers should conduct a final checklist to ensure all components of the dossier are complete, including:
- All sections of the CTD are filled out accurately and comprehensively.
- All required documents and forms are attached, including certificates of analysis, reference standards, and manufacturing licenses.
- Fees associated with the submission are paid in accordance with WHO guidelines.
Once submitted, WHO conducts a preliminary review of the documentation to check for completeness. If any issues arise during this evaluation, the WHO may request additional information or clarification from the manufacturer. This stage can often lead to exchanges of information that may prolong the review process but is ultimately aimed at ensuring that the quality of the product meets WHO expectations.
In addition to the preliminary review, the manufacturer should be prepared for potential site inspections. WHO will typically notify applicants of the impending inspections, during which evaluators will observe the manufacturing processes and facilities to further verify compliance with GMP. It is critical that manufacturing facilities are inspection-ready, with personnel trained and documentation readily available to provide to inspectors.
Step 5: WHO Review Process and Communication
The review process for WHO Prequalification is a rigorous and structured evaluation that often involves several layers of scrutiny. The WHO reviewers consist of experts who assess the submitted documentation according to the established criteria, including the quality of the product, safety, and efficacy data submissions.
The preliminary review can take various timeframes, depending on the complexity of the submission and the current workload of WHO. Manufacturers should be prepared to respond promptly to any inquiries raised during the review process, as timely communication can significantly impact the outcome.
Should the product be deemed acceptable, WHO may issue a recommendation for prequalification, indicating that the product has met necessary WHO standards, followed by listing on the WHO PQ database. This listing, along with the positive recommendation, can greatly enhance marketability and bolster trust among stakeholders.
However, if the product does not meet the standards set forth by WHO, the reviewing team will communicate the reasons for this decision and may offer suggestions for re-submission or improvements. Companies may have the opportunity to address concerns and submit revised documentation, though manufacturers should be wary that repeated submissions may prolong the approval timeline.
Through this review process, having solid regulatory compliance consulting can be invaluable. Consulting professionals can assist in ensuring that all submitted documents are comprehensive, clear, and compelling, which helps to enhance the chances of favorable outcomes during review stages.
Step 6: Post-Approval Commitments and Surveillance
After receiving WHO Prequalification, manufacturers must adhere to post-approval commitments to ensure ongoing compliance with WHO regulations. This stage is critical as it influences the continued market presence of their products. Companies are required to conduct ongoing monitoring of the production processes and maintain robust quality assurance systems.
One of the primary responsibilities includes regular reporting to WHO on quality control measures, including adverse events associated with the approved products as part of pharmacovigilance commitments. These reports help WHO maintain a high level of safety for patients using prequalified medicines globally.
Additionally, manufacturers must ensure they remain compliant with any newly established WHO guidelines or amendments to previous regulations. They should also engage in routine inspections, as scheduled and unscheduled audits from WHO may occur to assess ongoing compliance with GMP standards.
- Continuous Quality Improvement: Establish a framework for the continual assessment of the QA/QC systems against evolving WHO standards.
- Training: Ensure all staff involved in production and quality control receive regular training on WHO regulations and GMP standards.
- Documentation: Maintain detailed records of every batch produced, along with testing results and any corrective actions taken when standard practices are not followed.
Non-compliance to these post-approval commitments can lead to de-listing from the WHO PQ, which significantly impacts market access, revenue, and organizational credibility. Hence, ongoing regulatory compliance consulting plays an essential role in supporting companies to navigate these commitments effectively, ensuring they stay compliant at every stage of the product lifecycle.
Conclusion: Embracing WHO Prequalification for Competitive Advantage
In conclusion, the WHO Prequalification program represents a significant compliance pathway for manufacturers of medicines seeking to expand their presence in global markets, particularly in regions with high public health needs. By understanding the eligibility requirements, meticulously preparing documentation, adhering to submission and review protocols, and committing to post-approval surveillance, organizations can effectively utilize this program to enhance their product acceptance and market reach.
Engaging experienced regulatory compliance consulting service providers can immensely simplify this complex process. These experts can guide companies through the minutiae of WHO regulations, ensuring that their processes and documents are consistent with international standards. As the global health landscape evolves, organizations that prioritize WHO PQ status will be better positioned to meet healthcare challenges and deliver critical healthcare solutions to underserved populations around the world.